{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:14:18Z","timestamp":1789874058702,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/leu.2015.80","type":"journal-article","created":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T07:33:19Z","timestamp":1426750399000},"page":"1721-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma"],"prefix":"10.1038","volume":"29","author":[{"given":"E K","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Haenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I W","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Schurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Huegle-Doerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Neben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-W","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Zeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gerecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I G H","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"key":"BFleu201580_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046\u20131060.","journal-title":"N Engl J Med"},{"key":"BFleu201580_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014; 99: 232\u2013242.","journal-title":"Haematologica"},{"key":"BFleu201580_CR3","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063\u20136073.","journal-title":"Blood"},{"key":"BFleu201580_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosinol","year":"2012","unstructured":"Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood 2012; 120: 1589\u20131596.","journal-title":"Blood"},{"key":"BFleu201580_CR5","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119: 4375\u20134382.","journal-title":"Blood"},{"key":"BFleu201580_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010; 28: 800\u2013807.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR7","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IGH, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946\u20132955.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR8","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"J-L Harousseau","year":"2010","unstructured":"Harousseau J-L, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621\u20134629.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR9","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279\u20133287.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR10","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","volume":"117","author":"P Moreau","year":"2011","unstructured":"Moreau P, Attal M, Pegourie B, Planche L, Hulin C, Facon T et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011; 117: 3041\u20133044.","journal-title":"Blood"},{"key":"BFleu201580_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/sj.bmt.1705307","volume":"37","author":"D O\u2019Shea","year":"2006","unstructured":"O\u2019Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731\u2013737.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu201580_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2141.2005.05514.x","volume":"129","author":"CL Alvares","year":"2005","unstructured":"Alvares CL, Davies FE, Horton C, Patel G, Powles R, Sirohi B et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005; 129: 607\u2013614.","journal-title":"Br J Haematol"},{"key":"BFleu201580_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","volume":"156","author":"ML Khan","year":"2012","unstructured":"Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A et al. A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012; 156: 326\u2013333.","journal-title":"Br J Haematol"},{"key":"BFleu201580_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23: 1337\u20131341.","journal-title":"Leukemia"},{"key":"BFleu201580_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3324\/haematol.11228","volume":"92","author":"FE Davies","year":"2007","unstructured":"Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ . The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica 2007; 92: 1149\u20131150.","journal-title":"Haematologica"},{"key":"BFleu201580_CR16","doi-asserted-by":"crossref","first-page":"59a","DOI":"10.1182\/blood.V114.22.131.131","volume":"114","author":"H Einsele","year":"2009","unstructured":"Einsele H, Liebisch P, Langer C, Kropff M, Wandt H, Jung W et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial). Blood 2009; 114: 59a\u201360a, Abstract # 131.","journal-title":"Blood"},{"key":"BFleu201580_CR17","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075\u20132085.","journal-title":"Lancet"},{"key":"BFleu201580_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV . Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2008; 23: 3\u20139.","journal-title":"Leukemia"},{"key":"BFleu201580_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFleu201580_CR20","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G et alMyeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFleu201580_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012; 119: 940\u2013948.","journal-title":"Blood"},{"key":"BFleu201580_CR23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG . Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873\u2013890.","journal-title":"Stat Med"},{"key":"BFleu201580_CR24","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/sim.4780091208","volume":"9","author":"CP Farrington","year":"1990","unstructured":"Farrington CP, Manning G . Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447\u20131454.","journal-title":"Stat Med"},{"key":"BFleu201580_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565\u20131571.","journal-title":"N Engl J Med"},{"key":"BFleu201580_CR26","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2013","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013; 28: 1122\u20131128.","journal-title":"Leukemia"},{"key":"BFleu201580_CR27","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","volume":"28","author":"AA Chanan-Khan","year":"2010","unstructured":"Chanan-Khan AA, Giralt S . Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612\u20132624.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR28","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"J-L Harousseau","year":"2009","unstructured":"Harousseau J-L, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood 2009; 114: 3139\u20133146.","journal-title":"Blood"},{"key":"BFleu201580_CR29","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025\u20133031.","journal-title":"Blood"},{"key":"BFleu201580_CR30","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","volume":"31","author":"P Kapoor","year":"2013","unstructured":"Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013; 31: 4529\u20134535.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFleu201580_CR32","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","volume":"115","author":"CB Reeder","year":"2010","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010; 115: 3416\u20133417.","journal-title":"Blood"},{"key":"BFleu201580_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679\u2013686.","journal-title":"Blood"},{"key":"BFleu201580_CR34","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the intergroupe Francophone du Myelome. J Clin Oncol 2014; 32: 2712\u20132717.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR35","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011; 118: 5752\u20135758.","journal-title":"Blood"},{"key":"BFleu201580_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","volume":"31","author":"H Ludwig","year":"2013","unstructured":"Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol 2013; 31: 247\u2013255.","journal-title":"J Clin Oncol"},{"key":"BFleu201580_CR37","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S et al. A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801\u20131809.","journal-title":"Blood"},{"key":"BFleu201580_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/bjh.13004","volume":"167","author":"CB Reeder","year":"2014","unstructured":"Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S et al. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 2014; 167: 563\u2013565.","journal-title":"Br J Haematol"},{"key":"BFleu201580_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbi.2014.01.020","volume":"38","author":"J Zhang","year":"2014","unstructured":"Zhang J, Su Y-M, Li D, Cui Y, Huang Z-Z, Wei J-Y et al. TNF-\u03b1-mediated JNK activation in the dorsal root ganglion neurons contributes to bortezomib-induced peripheral neuropathy. Brain Behav Immun 2014; 38: 185\u2013191.","journal-title":"Brain Behav Immun"},{"key":"BFleu201580_CR40","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","volume":"119","author":"S Ravaglia","year":"2008","unstructured":"Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008; 119: 2507\u20132512.","journal-title":"Clin Neurophysiol"},{"key":"BFleu201580_CR41","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431\u2013440.","journal-title":"Lancet Oncol"},{"key":"BFleu201580_CR42","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1182\/blood.V124.21.3475.3475","volume":"124","author":"M Merz","year":"2014","unstructured":"Merz M, Salwender H-J, Hanel M, Bertsch U, Kunz C, Hielscher T et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma \u2013 subgroup analysis from the GMMG-MM5 trial. Blood 2014; 124: 3475.","journal-title":"Blood"},{"key":"BFleu201580_CR43","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.3324\/haematol.2014.110221","volume":"99","author":"A Brioli","year":"2014","unstructured":"Brioli A, Zannetti BA, Zamagni E, Tacchetti P, Pantani L, Mancuso K et al. Peripheral neuropathy induced by subcutaneous bortezomib\u2010based induction therapy for newly diagnosed multiple myeloma. Haematologica 2014; 99: e242\u2013e243.","journal-title":"Haematologica"},{"key":"BFleu201580_CR44","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau J-L et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144: 895\u2013903.","journal-title":"Br J Haematol"},{"key":"BFleu201580_CR45","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","volume":"100","author":"M Zangari","year":"2002","unstructured":"Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168\u20131171.","journal-title":"Blood"},{"key":"BFleu201580_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2141.2005.05848.x","volume":"132","author":"H Hassoun","year":"2006","unstructured":"Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155\u2013161.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201580","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:22:22Z","timestamp":1648743742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFleu201580"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.80","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]},"assertion":[{"value":"3 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EKM received travel grants from Janssen-Cilag, Celgene, Onyx and Mundipharma. JD received honoraria from Janssen-Cilag, Celgene, Roche and GSK, and compensation for his consulting\/advisory roles for Janssen-Cilag, Roche and GSK. MMu received honoraria from Celgene as well as travel grants from Mundipharma and Celgene. DH received compensation for his consulting\/advisory role from Celgene and also received research funding from Novartis and Celgene. JH received honoraria from Celgene and Janssen-Cilag. IGHS-W received compensation for his consulting\/advisroy role from Janssen-Cilag. KW received honoraria from Celgene, Janssen-Cilag and Onyx; received compensation for her consulting\/advisory role at Celgene, Janssen, Onyx and Noxxon; and also received research funding from Celgene and travel grants from Celgene and Janssen-Cilag. CS received honoraria and compensation for his consulting\/advisory role from Janssen-Cilag and Celgene. HS received honoraria from Celgene, Janssen-Cilag, Chugai, Novartis, Mundipharma, TEVA, Roche, Binding Site and BMS; received compensation for his consulting\/advisory role at Celgene, Janssen-Cilag, BMS, Novartis and TEVA; received research funding from Celgene, Janssen-Cilag, Novartis and BMS; and also received travel grants from Celgene, Janssen-Cilag, Novartis, TEVA and Roche. HG received honoraria from Janssen-Cilag, Celgene, Novartis, Onyx and Millennium; has a consulting\/advisory role at Janssen-Cilag, Celgene, Novartis, Onyx and Millennium; received compensation as a member of the speakers bureau from Janssen-Cilag, Celgene, Novartis, Onyx, Millennium and Chugai; and also received research funding from Janssen-Cilag, Celgene, Novartis and Chugai. UB, CK, MH, IWB, AJ, BS, TH, MMe, BH-D, AS, MSR, KN, H-WL, MZ and CG declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}